Agenus Inc. (AGEN) Expected to Announce Quarterly Sales of $15.58 Million
Brokerages expect Agenus Inc. (NASDAQ:AGEN) to post $15.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Agenus’ earnings. The highest sales estimate is $27.60 million and the lowest is $3.56 million. Agenus reported sales of $5.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 179.2%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Agenus will report full-year sales of $15.58 million for the current financial year, with estimates ranging from $38.08 million to $63.00 million. For the next fiscal year, analysts expect that the business will post sales of $21.46 million per share. Zacks’ sales calculations are an average based on a survey of research analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.37). The firm had revenue of $3.40 million during the quarter, compared to the consensus estimate of $5.91 million. The firm’s revenue for the quarter was down 24.4% on a year-over-year basis.
Shares of Agenus (NASDAQ AGEN) opened at $3.84 on Tuesday. The company has a debt-to-equity ratio of -2.39, a quick ratio of 1.55 and a current ratio of 1.55. Agenus has a fifty-two week low of $3.20 and a fifty-two week high of $5.45.
In other news, CEO Garo H. Armen bought 100,000 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were bought at an average cost of $3.55 per share, with a total value of $355,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.90% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. TIAA CREF Investment Management LLC raised its holdings in Agenus by 0.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 204,576 shares of the biotechnology company’s stock valued at $800,000 after acquiring an additional 1,283 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Agenus by 6.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 4,006 shares during the period. Metropolitan Life Insurance Co. NY raised its holdings in Agenus by 12.2% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 6,101 shares during the period. Voya Investment Management LLC raised its holdings in Agenus by 18.5% in the 2nd quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 6,381 shares during the period. Finally, Teachers Advisors LLC raised its holdings in Agenus by 9.7% in the 2nd quarter. Teachers Advisors LLC now owns 141,776 shares of the biotechnology company’s stock valued at $554,000 after acquiring an additional 12,509 shares during the period. 37.90% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Agenus Inc. (AGEN) Expected to Announce Quarterly Sales of $15.58 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/05/agenus-inc-agen-expected-to-announce-quarterly-sales-of-15-58-million.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.